PROs support dostarlimab plus chemotherapy as a new standard of care in endometrial cancer
Data from selected patients in the RUBY trial show improvements in QoL domains over the course of treatment and benefits compared with placebo
Checkpoint inhibition improves outcomes in high-risk, locally advanced cervical cancer
In the KEYNOTE-A18 study, the combination of pembrolizumab and concurrent chemoradiotherapy significantly improved progression-free survival
First-line immunotherapy prolongs survival in advanced or recurrent endometrial cancer
Results from the RUBY trial show improvements both in progression-free survival and overall survival in patients treated with dostarlimab plus standard chemotherapy, indicating a new standard of care
HPV vaccination uptake reflects our efforts as one oncology community
Cervical cancer is a preventable disease so, although research advances are increasing treatment opportunities for all women diagnosed at any stage, we must stop it before it hits.
Prevention and early detection are pivotal in LMICs, but not enough
While locally tailored cancer screening programmes, particularly for cervical cancer, are showing encouraging results in some areas with limited resources, cancer care is still suffering some bottlenecks due to lack of training for healthcare staff and shortages of medicines